Aims and Scope
The British Journal of Cancer (BJC) is one of the most cited general cancer journals, it is committed to publishing cutting edge discovery, translational and clinical cancer research. The BJC aims to provide a global platform to disseminate important research within the broad spectrum of oncology. The journal welcomes research across all cancer types and has a focus on: metastasis, microenvironment, immunology and immunotherapy, targeted and next-generation therapeutics, chemotherapy and radiotherapy, mechanisms of resistance, clinical trials, genomics, epigenomics and precision medicine, epidemiology, metabolism and state-of-the art diagnostic approaches.
The BJC is published in association with Cancer Research UK, the world’s leading independent cancer charity dedicated to saving lives through research.
Submit your next manuscript to BJC and benefit from:
- International and highly respected editorial team
- Rapid decision and publication times
- High exposure and article visibility via nature.com
- Funder-compliant open access options available
- Engaged and growing Twitter following at @BrJCancer
- Share your article through SharedIt: Springer Nature’s content-sharing initiative allowing authors and subscribers to share links to view-only, full-text articles from this journal
BJC publishes across the following six subject categories:
- Clinical Studies
- Translational Therapeutics
- Molecular Diagnostics
- Genetics and Genomics
- Cellular and Molecular Biology
Translational Therapeutics is dedicated to scientific work that has possible direct applicability in clinical uses or opens new avenues for treatments. The type of manuscript ranges from basic research to early informative clinical trials with extensive concomitant biomaterial analyses. Translational concepts include new computational or wet lab Technologies as well.
The Molecular Diagnostic subject category considers studies that examine genomic, transcriptomic, epigenomic, and proteomic biomarkers in the context of cancer diagnosis, staging, prognosis, therapeutic prediction, and radiographic and pathologic characteristics. We are particularly interested in papers that explore novel or evolving biomarkers with direct clinical applicability in cancer care.
Genetics and Genomics
This subject category covers the use of genetic epidemiology and bioinformatics, together with molecular and cell biology, to identify and characterise the genetic and epigenetic factors underlying tumour development and progression. We are interested in papers which focus on the mechanistic consequences of genetic variance, and adequately powered studies of how genetic and epigenetic variation impacts patient risk and outcome phenotypes, in particular where these point to new clinical approaches. Wherever possible, bioinformatics analyses should be supported by experimental results.
Cellular and Molecular Biology
The Cellular and Molecular Biology subject category considers studies that provide novel insight into basic cellular and molecular mechanisms of cancer, but are not biomarker, methodology, or pathology focused. Studies considered for this category will generally go beyond in vitro and/or in silico evaluation of basic cellular and molecular mechanisms of cancer, and usually include the use of appropriate in vivo model systems. Findings of studies considered for this category should be clinically and/or therapeutically applicable.
The Epidemiology subject category focuses on prevention, early detection, and factors that influence the risk and prognosis of cancer.
To explore the type of articles that the BJC publishes, please browse our subject pages.
Article metrics such as number of downloads, citations and online attention are available from each article page, and provide an overview of the attention received by a paper.
2022 Citation Metrics
2-year Impact Factor*: 8.8
5-year Impact Factor*: 8.4
Immediacy index*: 1.2
Eigenfactor® score*: 0.03984
Article influence score*: 2.4
Journal Citation Indicator*: 1.38
*2022 Journal Citation Reports® Science Edition (Clarivate Analytics, 2023)
**Source-normalized Impact per Paper (Scopus)
***SCImago Journal Rank (Scopus)
2022 Peer Review Metrics
Submission to first editorial decision: 10 days
Submission to Accept: 167 days
2022 Usage Metrics
Altmetric mentions: 31,531
All articles published in the BJC are included in:
EBSCO Discovery Service
Science Citation Index
Science Citation Index Expanded (SciSearch)
Current Contents / Clinical Medicine
Current Contents / Life Sciences
Summon by ProQuest
EBSCO Academic Search
EBSCO Advanced Placement Source
EBSCO Biomedical Reference Collection
EBSCO STM Source
EBSCO TOC Premier
The BJC now provides its latest table of contents as an RSS web feed. This allows users with an RSS reader to receive automatic updates whenever new content is added to these pages.
Receive the BJC's current issue table of contents.
Follow us on Twitter @BrJCancer
ISSN and eISSN